TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Revenue

Last Annual Value

605.49M

3-Year CAGR

86%

5-Year CAGR

88%

10-Year CAGR

58%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of Revenue

TMDX · NASDAQ
CompanyRevenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
605.49M
35.8%82.1%58.1% 
0.00
N/AN/AN/A
507.44M
17.3%11.5%16.1%
3.44B
5.0%7.3%7.9%
587.86M
26.2%N/AN/A
39.20M
-20.7%-11.7%N/A
1.24B
4.3%9.4%2.5%
22.50M
16.9%N/AN/A
11.70B
25.9%43.5%N/A
5.65B
9.5%10.4%19.7%
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
0.00
N/AN/AN/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69